DK1998805T3 - Tumorterapi med et antistof til vaskulær endotelial vækstfaktor og et antistof til human epitelial vækstfaktor receptor type 2 - Google Patents

Tumorterapi med et antistof til vaskulær endotelial vækstfaktor og et antistof til human epitelial vækstfaktor receptor type 2

Info

Publication number
DK1998805T3
DK1998805T3 DK07711981.6T DK07711981T DK1998805T3 DK 1998805 T3 DK1998805 T3 DK 1998805T3 DK 07711981 T DK07711981 T DK 07711981T DK 1998805 T3 DK1998805 T3 DK 1998805T3
Authority
DK
Denmark
Prior art keywords
antibody
growth factor
epitelial
human
receptor type
Prior art date
Application number
DK07711981.6T
Other languages
English (en)
Inventor
Thomas Friess
Max Hasmann
Werner Scheuer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37998279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1998805(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1998805T3 publication Critical patent/DK1998805T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
DK07711981.6T 2006-03-22 2007-03-20 Tumorterapi med et antistof til vaskulær endotelial vækstfaktor og et antistof til human epitelial vækstfaktor receptor type 2 DK1998805T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06111523 2006-03-22
EP06021815 2006-10-18
PCT/EP2007/002448 WO2007107329A1 (en) 2006-03-22 2007-03-20 Tumor therapy with an antibody for vascular endothelial groeth factor and an antibody for human epithelial growth factor receptor type 2

Publications (1)

Publication Number Publication Date
DK1998805T3 true DK1998805T3 (da) 2012-10-08

Family

ID=37998279

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07711981.6T DK1998805T3 (da) 2006-03-22 2007-03-20 Tumorterapi med et antistof til vaskulær endotelial vækstfaktor og et antistof til human epitelial vækstfaktor receptor type 2
DK11164996.8T DK2364732T3 (da) 2006-03-22 2007-03-20 Tumorterapi med et antistof til vaskulær endotelvækstfaktor og et antistof til human epitelvækstfaktorreceptor type 2

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11164996.8T DK2364732T3 (da) 2006-03-22 2007-03-20 Tumorterapi med et antistof til vaskulær endotelvækstfaktor og et antistof til human epitelvækstfaktorreceptor type 2

Country Status (25)

Country Link
US (4) US20070224203A1 (da)
EP (2) EP1998805B1 (da)
JP (2) JP5795463B2 (da)
KR (1) KR101089070B1 (da)
AR (1) AR059982A1 (da)
BR (1) BRPI0709025A2 (da)
CA (1) CA2645891A1 (da)
CR (1) CR10244A (da)
DK (2) DK1998805T3 (da)
EC (1) ECSP088753A (da)
ES (2) ES2392873T3 (da)
HK (1) HK1131037A1 (da)
HU (1) HUE029615T2 (da)
IL (1) IL193675A0 (da)
MA (1) MA30290B1 (da)
MX (1) MX2008012014A (da)
MY (1) MY151449A (da)
NO (1) NO20083761L (da)
NZ (1) NZ570921A (da)
PL (2) PL2364732T3 (da)
RU (1) RU2538664C2 (da)
SG (1) SG170730A1 (da)
SI (2) SI2364732T1 (da)
TW (1) TW200812615A (da)
WO (1) WO2007107329A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
KR20030007640A (ko) * 2000-05-19 2003-01-23 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
RS20050885A (sr) 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
BRPI0513681A (pt) * 2004-07-22 2008-05-13 Genentech Inc composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101115849A (zh) * 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
RU2404806C2 (ru) 2005-02-23 2010-11-27 Дженентек, Инк. Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
ES2392630T3 (es) * 2006-08-21 2012-12-12 F. Hoffmann-La Roche Ag Terapia antitumoral con anticuerpos anti-VEGF
CL2008000614A1 (es) 2007-03-02 2008-09-05 Genentech Inc F Hoffmann La Ro Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her.
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
WO2012169822A2 (ko) * 2011-06-10 2012-12-13 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
CN117018187A (zh) 2011-10-14 2023-11-10 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
KR101774121B1 (ko) 2012-07-13 2017-09-01 로슈 글리카트 아게 이중특이적 항-vegf/항-ang-2 항체 및 안 혈관 질환의 치료에 있어서 이의 용도
NZ711567A (en) 2013-03-13 2020-04-24 Genentech Inc Antibody formulations
BR112015024926A2 (pt) 2013-04-16 2017-10-10 Genentech Inc composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe
CN106163558A (zh) 2014-04-25 2016-11-23 豪夫迈·罗氏有限公司 用曲妥珠单抗‑mcc‑dm1和帕妥珠单抗治疗早期乳腺癌的方法
US20160137727A1 (en) 2014-09-15 2016-05-19 Genentech, Inc. Antibody formulations
WO2016196373A2 (en) 2015-05-30 2016-12-08 Genentech, Inc. Methods of treating her2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) * 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CA3046092A1 (en) 2016-12-28 2018-07-05 Genentech, Inc. Treatment of advanced her2 expressing cancer
KR20200113292A (ko) 2017-01-17 2020-10-06 제넨테크, 인크. 피하 her2 항체 제형
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
EP1975181B1 (en) 1992-10-28 2011-02-16 Genentech, Inc. Use of vascular endothelial cell growth factor antagonists
US6071935A (en) 1996-06-27 2000-06-06 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
IL129354A0 (en) 1996-10-18 2000-02-17 Genentech Inc Anti-ErbB2 antibodies
ES2361267T3 (es) 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
JP3957765B2 (ja) * 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
PL348634A1 (en) 1998-05-15 2002-06-03 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EA200100135A1 (ru) 1998-08-27 2001-08-27 Пфайзер Продактс Инк. Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
ES2237125T3 (es) 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
ES2301254T3 (es) 1998-11-18 2008-06-16 Genentech, Inc. Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales.
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU1687500A (en) 1998-12-16 2000-07-03 Kyowa Hakko Kogyo Co. Ltd. Antihuman vegf monoclonal antibody
AU775806B2 (en) * 1998-12-22 2004-08-19 Genentech Inc. Vascular endothelial cell growth factor antagonists and uses thereof
TR200201296T2 (tr) 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
EP1157041B1 (en) 1999-03-01 2005-06-01 Genentech, Inc. Antibodies for cancer therapy and diagnosis
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
BR0010017A (pt) * 1999-04-28 2002-06-11 Univ Texas Composições e processos para o tratamento de câncer por inibição seletiva de vegf
CA2374085C (en) 1999-05-14 2015-12-29 Genentech, Inc. Tumour treatment with anti-erbb2 antibodies
PT1189634E (pt) 1999-06-25 2007-06-06 Genentech Inc Tratamento de cancro da próstata com anticorpos anti-erbb2.
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
NZ531426A (en) 1999-06-25 2005-10-28 Genentech Inc Method of treating cancer wherein the cancer expresses epidermal growth factor receptor comprising administration of humanized anti-ErbB2 antibodies
DE60017179T2 (de) * 1999-10-19 2006-01-05 Merck & Co., Inc. Tyrosin kinaseinhibitoren
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
TR200400342T4 (tr) 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil protein transferazı önlemek için kinolin türevleri.
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2003077841A2 (en) 2002-03-12 2003-09-25 The General Hospital Corporation Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
DK1501856T3 (da) 2002-04-10 2013-03-25 Genentech Inc Anti-HER2 antistofvarianter
RS20050885A (sr) 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
US20040243207A1 (en) 2003-05-30 2004-12-02 Olson Donald R. Medical implant systems
EP1664115A2 (en) 2003-08-01 2006-06-07 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
ATE554107T1 (de) 2003-12-19 2012-05-15 Genentech Inc Als therapeutika geeignete monovalente antikörperfragmente
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

Also Published As

Publication number Publication date
SI1998805T1 (sl) 2012-12-31
JP2009530333A (ja) 2009-08-27
EP1998805B1 (en) 2012-08-22
EP2364732B1 (en) 2016-07-06
ECSP088753A (es) 2008-10-31
US20110064736A1 (en) 2011-03-17
IL193675A0 (en) 2011-08-01
CR10244A (es) 2008-10-29
MX2008012014A (es) 2008-10-01
WO2007107329A1 (en) 2007-09-27
AU2007229008A1 (en) 2007-09-27
EP2364732A1 (en) 2011-09-14
MA30290B1 (fr) 2009-03-02
KR101089070B1 (ko) 2011-12-05
RU2008141433A (ru) 2010-04-27
US20070224203A1 (en) 2007-09-27
AR059982A1 (es) 2008-05-14
SG170730A1 (en) 2011-05-30
HUE029615T2 (en) 2017-03-28
HK1131037A1 (en) 2010-01-15
ES2595238T3 (es) 2016-12-28
NO20083761L (no) 2008-10-09
PL2364732T3 (pl) 2017-01-31
CA2645891A1 (en) 2007-09-27
US9090700B2 (en) 2015-07-28
NZ570921A (en) 2011-09-30
JP5795463B2 (ja) 2015-10-14
KR20080096598A (ko) 2008-10-30
ES2392873T3 (es) 2012-12-14
RU2538664C2 (ru) 2015-01-10
JP2012207036A (ja) 2012-10-25
DK2364732T3 (da) 2016-10-10
EP1998805A1 (en) 2008-12-10
US20170239353A1 (en) 2017-08-24
PL1998805T3 (pl) 2013-01-31
BRPI0709025A2 (pt) 2011-06-21
SI2364732T1 (sl) 2016-12-30
US20150283238A1 (en) 2015-10-08
MY151449A (en) 2014-05-30
TW200812615A (en) 2008-03-16

Similar Documents

Publication Publication Date Title
DK1998805T3 (da) Tumorterapi med et antistof til vaskulær endotelial vækstfaktor og et antistof til human epitelial vækstfaktor receptor type 2
CY2016016I2 (el) Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
CY2017013I1 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
PL2532679T3 (pl) Ludzkie przeciwciała przeciwko IL13 i zastosowania terapeutyczne
EP1720575A4 (en) Therapeutic and diagnostic conjugates for use with multi-specific antibodies
ZA200806723B (en) Combination therapy using anti-EGFR and anti-Her2 antibodies
DK2179379T3 (da) Terapiindgivelsessystem med åben opbygning og fremgangsmåde deraf
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
IL231169A0 (en) Human monoclonal antibodies to fucosil - 1gm and methods of using antibodies against fucosil - 1gm
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
EP2158217A4 (en) THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR NEUTRALIZING HUMAN MONOCLONAL ANTIBODY AND APPLICATION THEREOF
DK1951866T3 (da) Delta-9-elongaser og anvendelse heraf til fremstilling af flerumættede fedtsyrer
DK2121989T4 (da) K-ras-mutationer og anti-EGFR-antistofbehandling
IL225386A0 (en) Diagnosis and treatment of cancer using anti-ereg antibody
BRPI0810270A2 (pt) "implante de válvula cardíaca e método de implante"
EP2050466A4 (en) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-DESMOGLEIN ANTIBODY-3
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
EP1789027A4 (en) Therapeutic Use of Anti- TF Antigen Antibodies
DK1773829T3 (da) Aminotropanderivater, fremstilling og terapeutiske anvendelser heraf
DK1940840T3 (da) 6-heteroarylpyridoindolon-derivater, fremstilling deraf og terapeutisk anvendelse deraf
HK1155670A1 (en) Therapeutic use of anti-cs1 antibodies
EP1952826A4 (en) DIAGNOSTIC AGENT AND THERAPEUTIC AGENT FOR DISEASES RELATED TO THE HEPATOCYTE GROWTH FACTOR RECEPTOR
DK1742947T3 (da) 6-substituerede pyridoindolanderivater, fremstilling og terapeutisk anvendelse heraf
EP2070547A4 (en) THERAPEUTIC COMPOSITIONS TO TREAT THE EFFECT OF ANTIBODY THERAPY AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR
ZA200802541B (en) Human antibodies against IL13 and therapeutic uses